GSK moved to expand late-stage development of its gynecological cancer antibody-drug conjugate (ADC) licensed from Hansoh Pharma, outlining a plan for five Phase 3 studies. The update follows early encouraging data released by GSK for the ADC, and signals a commitment to broaden clinical evidence across multiple gynecologic indications or study designs as the asset approaches pivotal timelines. For ADC developers, the shift toward multi-study Phase 3 programs can accelerate label-defining data packages while supporting differentiated use cases across a competitive oncology landscape. The report ties the Phase 3 plan directly to GSK’s licensed asset from Hansoh, underscoring continuing cross-border ADC collaboration as Western and Chinese groups scale development.